BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Irinotecan: trial readouts and FDA decisions

5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, AbbVie, Beijing Konruns Pharmaceutical Co., Ltd., CStone Pharmaceuticals, Akeso, LaNova Medicines Zhejiang Co., Ltd., Merck Sharp & Dohme LLC, Taiho Oncology, Inc., Beijing Konruns Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., LaNova Medicines Zhejiang Co., Ltd., Taiho Oncology, Inc., Idience Co., Ltd., Revolution Medicines, Inc., Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2AbbVie ABBVNCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable MetUnresectable Metastatic Colorectal Canceractive not recruiting280
2026-12-30 est.P3Beijing Konruns Pharmaceutical Co., Ltd.NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerEsophageal Squamous Cell Carcinomarecruiting490
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-13 est.P3AkesoNCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal CancerColorectal Adenocarcinomarecruiting560
2026-12-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinomaactive not recruiting464

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11-10 est.P3LaNova Medicines Zhejiang Co., Ltd.NCT06351020 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Locally Advanced or Metastatic GC and GCJ Adenocarcinomaactive not recruiting387
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-07-31 est.P1/P2Idience Co., Ltd.NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerGastric Canceractive not recruiting87
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.